Astec Lifesciences Ltd

- No explicit mention of any current or future fundraising through debt or equity in the provided transcript. - The company has discussed CAPEX plans totaling around ₹150 crores for the current year and ₹300-350 crores over the next 3 years focused on new plants, R&D facilities, and other projects. - No specific details were given on how this CAPEX would be funded, such as through debt, equity, or internal accruals. - Management did not indicate any plans for raising capital via equity or debt during the Q&A or closing remarks. - Thus, based on the transcript, there is no disclosed fundraising plan through debt or equity at this time.

- Current year CAPEX plan is ₹150 crores. - Next 3 years planned investments are ₹300-350 crores. - Investments include: - New herbicide plant (already started construction post-monsoon; ~₹100+ crores). - New state-of-the-art Research & Development (R&D) facility (expected completion by Q3 of next financial year). - New triazole fungicide plant for 3 major new molecules (construction to start after monsoon, ~1 year project duration). - Other miscellaneous projects contributing to ₹150 crores CAPEX this year. - Additional CAPEX on CMO side will be done as new molecules come up after utilizing the herbicide plant's spare capacity. - R&D expansion will increase molecule development capacity multifold. - Debottlenecking measures will drive volume growth in enterprise business with limited CAPEX.

- Enterprise business volume growth expected at 20% to 25% year-on-year driven by debottlenecking and new product introductions. - CMO (Contract Manufacturing Organization) business growth forecasted at 6% to 8% for the current year, including contribution from the new herbicide plant. - The new herbicide plant expected to add about ₹70-80 crores in sales turnover by the second year of operation with gradual ramp-up over three years. - Introduction of 4 new CMO products this year, with some revenue starting in the current year and ramping up in subsequent years. - Three additional new triazole fungicide molecules expected to be commercialized next year with a CAPEX over ₹100 crores, targeting a significant market opportunity exceeding $1 billion. - Overall goal to increase CMO share from current ~20%, enhancing blended margins and driving accelerated growth in coming years.

- Enterprise business volume growth expected at 20% to 25% year-on-year, driven by debottlenecking and herbicide plant output. - Contract Manufacturing Organization (CMO) business projected to grow 6% to 8% in FY22, including contributions from the new herbicide plant. - CMO growth to accelerate in coming years as inventory issues resolve and new projects commence. - Introduction of 4 new CMO products and 1 enterprise product expected to drive revenue growth, with additional 3 new triazole fungicide molecules launching next year, supported by over ₹100 crore CAPEX. - EBITDA margin targeted to improve incrementally (0.5% to 1%) as CMO share increases, with current CMO margins approximately 5% higher than enterprise sales. - Overall, management indicates moderate near-term growth with potential for faster expansion and improved profitability alongside capacity ramp-up and new product launches.

- The transcript does not explicitly mention the current or expected order book or pending orders in precise figures. - However, it reflects ongoing strong demand for products, both domestic and international, with new contract manufacturing orders expected to grow moderately by 7-8% in the current fiscal year. - The company is launching 4 new contract manufacturing (CMO) molecules and 1 enterprise sales product this year. - The new herbicide plant and ongoing debottlenecking efforts are expected to add to volumes and revenues in the near term. - The triazole fungicide plant construction is starting soon, with capacity building expected to drive growth in subsequent years. - Registration and regulatory processes for new molecules are underway, supporting future commercial production and order fulfillment. - Customers have a history with the company; long-term contracts (3 years rolling for CMO) indicate stable future order flow.